Mohsen Khademi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7564413/publications.pdf

Version: 2024-02-01

52 papers	4,007 citations	159585 30 h-index	182427 51 g-index
55 all docs	55 docs citations	55 times ranked	6800 citing authors

#	Article	IF	Citations
1	Identification of four novel T cell autoantigens and personal autoreactive profiles in multiple sclerosis. Science Advances, 2022, 8, eabn1823.	10.3	17
2	Copy number variations across the bloodâ€“brain barrier in multiple sclerosis. Annals of Clinical and Translational Neurology, 2022, 9, 962-976.	3.7	2
3	Bâ€cell repopulation dynamics and drug pharmacokinetics impact <scp>SARSâ€CoV</scp>â€2 vaccine efficacy in <scp>antiâ€CD20</scp>â€treated multiple sclerosis patients. European Journal of Neurology, 2022, 29, 3317-3328.	3.3	13
4	Small noncoding RNA profiling across cellular and biofluid compartments and their implications for multiple sclerosis immunopathology. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	15
5	Assessing the Preanalytical Variability of Plasma and Cerebrospinal Fluid Processing and Its Effects on Inflammation-Related Protein Biomarkers. Molecular and Cellular Proteomics, 2021, 20, 100157.	3.8	15
6	Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis. IScience, 2021, 24, 103078.	4.1	36
7	Deep characterization of paired chromatin and transcriptomes in four immune cell types from multiple sclerosis patients. Epigenomics, 2021, 13, 1607-1618.	2.1	4
8	Oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the CNS. Acta Neuropathologica Communications, 2020, 8, 207.	5.2	11
9	Inflammation-related plasma and CSF biomarkers for multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12952-12960.	7.1	102
10	Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. Neurology, 2020, 94, e2457-e2467.	1.1	61
11	Diagnostic accuracy of intrathecal kappa free light chains compared with OCBs in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e775.	6.0	16
12	Non-parametric combination analysis of multiple data types enables detection of novel regulatory mechanisms in T cells of multiple sclerosis patients. Scientific Reports, 2019, 9, 11996.	3.3	13
13	GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis. Nature Medicine, 2019, 25, 1290-1300.	30.7	140
14	IL-22 Binding Protein Promotes the Disease Process in Multiple Sclerosis. Journal of Immunology, 2019, 203, 888-898.	0.8	13
15	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	9.0	455
16	Myelin oligodendrocyte glycoprotein revisitedâ€”sensitive detection of MOG-specific T-cells in multiple sclerosis. Journal of Autoimmunity, 2019, 102, 38-49.	6.5	30
17	Mass spectrometry-based analysis of cerebrospinal fluid from arthritis patientsâ€”immune-related candidate proteins affected by TNF blocking treatment. Arthritis Research and Therapy, 2019, 21, 60.	3.5	10
18	Increased Serological Response Against Human Herpesvirus 6A Is Associated With Risk for Multiple Sclerosis. Frontiers in Immunology, 2019, 10, 2715.	4.8	63

#	Article	IF	Citations
19	B cell alterations during BAFF inhibition with belimumab in SLE. EBioMedicine, 2019, 40, 517-527.	6.1	88
20	miRâ€31 regulates energy metabolism and is suppressed in TÂcells from patients with SjÃ¶gren's syndrome. European Journal of Immunology, 2019, 49, 313-322.	2.9	10
21	Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Multiple Sclerosis Journal, 2018, 24, 1046-1054.	3.0	149
22	Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis. Cell, 2018, 175, 85-100.e23.	28.9	350
23	Identification of MS-specific serum miRNAs in an international multicenter study. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e491.	6.0	59
24	Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 62-71.	3.0	81
25	Antibody Affinity Against 2009 A/H1N1 Influenza and Pandemrix Vaccine Nucleoproteins Differs Between Childhood Narcolepsy Patients and Controls. Viral Immunology, 2017, 30, 590-600.	1.3	4
26	Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsingâ€remitting multiple sclerosis. Journal of Neurochemistry, 2017, 141, 296-304.	3.9	124
27	Autoantibody targets in vaccine-associated narcolepsy. Autoimmunity, 2016, 49, 421-433.	2.6	25
28	Complement Receptor 2 is increased in cerebrospinal fluid of multiple sclerosis patients and regulates C3 function. Clinical Immunology, 2016, 166-167, 89-95.	3.2	19
29	Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e219.	6.0	92
30	Absence of systemic oxidative stress and increased CSF prostaglandin F _{2Î±} in progressive MS. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e256.	6.0	15
31	Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 7864-7869.	7.1	145
32	Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e191.	6.0	69
33	Anoctamin 2 identified as an autoimmune target in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 2188-2193.	7.1	86
34	Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms. Brain, Behavior, and Immunity, 2016, 51, 47-55.	4.1	56
35	Von Willebrand Factor Gene Variants Associate with Herpes simplex Encephalitis. PLoS ONE, 2016, 11, e0155832.	2.5	6
36	Hexosylceramides as intrathecal markers of worsening disability in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1271-1279.	3.0	43

#	Article	IF	Citations
37	Î³-secretase directly sheds the survival receptor BCMA from plasma cells. Nature Communications, 2015, 6, 7333.	12.8	267
38	Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid. Journal of Neuroinflammation, 2015, 12, 235.	7.2	86
39	The Immunoregulator Soluble TACI Is Released by ADAM10 and Reflects B Cell Activation in Autoimmunity. Journal of Immunology, 2015, 194, 542-552.	0.8	99
40	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain, 2015, 138, 918-931.	7.6	147
41	Age-dependent effects on the treatment response of natalizumab in MS patients. Multiple Sclerosis Journal, 2015, 21, 48-56.	3.0	19
42	Complement Component C3 and Butyrylcholinesterase Activity Are Associated with Neurodegeneration and Clinical Disability in Multiple Sclerosis. PLoS ONE, 2015, 10, e0122048.	2.5	52
43	JC Polyomavirus Infection Is Strongly Controlled by Human Leucocyte Antigen Class II Variants. PLoS Pathogens, 2014, 10, e1004084.	4.7	49
44	Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human TH cells. Nature Communications, 2014, 5, 5056.	12.8	137
45	A/H1N1 antibodies and TRIB2 autoantibodies in narcolepsy patients diagnosed in conjunction with the Pandemrix vaccination campaign in Sweden 2009â€“2010. Journal of Autoimmunity, 2014, 50, 99-106.	6.5	41
46	Intense Inflammation and Nerve Damage in Early Multiple Sclerosis Subsides at Older Age: A Reflection by Cerebrospinal Fluid Biomarkers. PLoS ONE, 2013, 8, e63172.	2.5	69
47	Intravenous immunoglobulin treatment of the post-polio syndrome: sustained effects on quality of life variables and cytokine expression after one year follow up. Journal of Neuroinflammation, 2012, 9, 167.	7.2	28
48	Unexpected finding of anticitrullinated protein antibodies in cerebrospinal fluid of RA patients with intact blood brain barrier. Annals of the Rheumatic Diseases, 2012, 71, A36.1-A36.	0.9	0
49	Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Multiple Sclerosis Journal, 2011, 17, 335-343.	3.0	213
50	Gene expression profiling in multiple sclerosis: A disease of the central nervous system, but with relapses triggered in the periphery?. Neurobiology of Disease, 2010, 37, 613-621.	4.4	52
51	T Cell Ig- and Mucin-Domain-Containing Molecule-3 (TIM-3) and TIM-1 Molecules Are Differentially Expressed on Human Th1 and Th2 Cells and in Cerebrospinal Fluid-Derived Mononuclear Cells in Multiple Sclerosis. Journal of Immunology, 2004, 172, 7169-7176.	0.8	200
52	Increased reactivity to myelin oligodendrocyte glycoprotein peptides and epitope mapping in HLA DR2(15)+ multiple sclerosis. European Journal of Immunology, 1998, 28, 3329-3335.	2.9	108